Table 6.

Most frequently reported treatment emergent adverse events, regardless of causal relation to study medication. Values are numbers (%) of subjects

Adverse event	Ketotifen (n = 172)	Placebo (n = 173)	Levocabastine (n = 174)
Ocular
Blurred vision	2 (1.2)	3 (1.7)	2 (1.1)
Burning/stinging	1 (0.6)	1 (0.6)	3 (1.7)
Burning/stinging upon instillation	0 (0.0)	0 (0.0)	3 (1.7)
Conjunctivitis	1 (0.6)	2 (1.2)	4 (2.3)
Eye pain	2 (1.2)	3 (1.7)	2 (1.1)
Eyelid disorder	2 (1.2)	4 (2.3)	1 (0.6)
Itching	2 (1.2)	2 (1.2)	3 (1.7)
Dry eyes	3 (1.7)	1 (0.6)	1 (0.6)
Photophobia	2 (1.2)	2 (1.2)	1 (0.6)
Non-ocular
Headache	28 (16.3)	28 (16.2)	25 (14.4)
Rhinitis	9 (5.2)	6 (3.5)	10 (5.7)
Pharyngitis	3 (1.7)	8 (4.6)	5 (2.9)
Allergic reactions	3 (1.7)	6 (3.5)	2 (1.1)
Rash	5 (2.9)	2 (1.2)	3 (1.7)